1.1. Global siRNA Therapeutics Market

2.1. Research Objective

2.2. Product Overview

2.3. Market Segmentation

2.4. Qualitative Research
2.4.1. Primary Sources
2.4.2. Secondary Sources

2.5. Quantitative Research
2.5.1. Primary Sources
2.5.2. Secondary Sources

2.6. Breakdown of Primary Research Respondents, By Region

2.7. Assumption for Study

2.8. Market Size Estimation

2.9. Data Triangulation

3.1. Industry Value Chain Analysis
3.1.1. Oligonucleotide Synthesis, Phosphoramidite & Chemical Raw-Material Suppliers
3.1.2. Delivery Technology (GalNAc Conjugate, Lipid Nanoparticle) Developers
3.1.3. CDMO / API Manufacturing, Formulation & Fill-Finish Providers
3.1.4. Clinical Development, Regulatory Affairs & Specialty Distribution Partners
3.1.5. End Users (Hospitals, Specialty Clinics, Homecare)

3.2. Industry Outlook
3.2.1. Overview of the Global siRNA Therapeutics & RNA-Interference (RNAi) Industry
3.2.2. Transition from Rare/Metabolic to Broad-Population Cardiometabolic Indications & Extra-Hepatic Delivery
3.2.3. Standardized GalNAc CMC Platforms, Value-Based Pricing & M&A / Licensing-Driven Consolidation

3.3. PESTLE Analysis

3.4. Porter's Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrants
3.4.4. Threat of Substitutes
3.4.5. Intensity of Rivalry

3.5. Market Growth and Outlook
3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
3.5.2. Price Trend Analysis, By Delivery Technology

4.1. Competition Dashboard
4.1.1. Market Concentration Rate
4.1.2. Company Market Share Analysis (Value %), 2025
4.1.3. Competitor Mapping & Benchmarking

5.1. Market Dynamics and Trends
5.1.1. Growth Drivers
5.1.2. Restraints
5.1.3. Opportunity
5.1.4. Key Trends

5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
5.2.1. By Delivery Technology
5.2.1.1. Key Insights
5.2.1.1.1. GalNAc Conjugate
5.2.1.1.2. Lipid Nanoparticle
5.2.1.1.3. Polymer/Other
5.2.2. By Route
5.2.2.1. Key Insights
5.2.2.1.1. Subcutaneous
5.2.2.1.2. Intravenous
5.2.2.1.3. Intrathecal/CNS
5.2.3. By Indication
5.2.3.1. Key Insights
5.2.3.1.1. Rare/Metabolic
5.2.3.1.1.1. hATTR Amyloidosis
5.2.3.1.1.2. Hyperoxaluria
5.2.3.1.1.3. Porphyria
5.2.3.1.2. Cardiovascular/Dyslipidemia
5.2.3.1.3. Oncology
5.2.3.1.4. Others
5.2.4. By Distribution Channel
5.2.4.1. Key Insights
5.2.4.1.1. Hospital Pharmacy
5.2.4.1.2. Specialty Pharmacy
5.2.5. By End User
5.2.5.1. Key Insights
5.2.5.1.1. Hospitals
5.2.5.1.2. Specialty Clinics
5.2.5.1.3. Homecare
5.2.6. By Region
5.2.6.1. Key Insights
5.2.6.1.1. North America
5.2.6.1.1.1. The U.S.
5.2.6.1.1.2. Canada
5.2.6.1.1.3. Mexico
5.2.6.1.2. Europe
5.2.6.1.2.1. Western Europe
5.2.6.1.2.1.1. The UK
5.2.6.1.2.1.2. Germany
5.2.6.1.2.1.3. France
5.2.6.1.2.1.4. Italy
5.2.6.1.2.1.5. Spain
5.2.6.1.2.1.6. Rest of Western Europe
5.2.6.1.2.2. Eastern Europe
5.2.6.1.2.2.1. Poland
5.2.6.1.2.2.2. Russia
5.2.6.1.2.2.3. Rest of Eastern Europe
5.2.6.1.3. Asia Pacific
5.2.6.1.3.1. China
5.2.6.1.3.2. India
5.2.6.1.3.3. Japan
5.2.6.1.3.4. Australia & New Zealand
5.2.6.1.3.5. South Korea
5.2.6.1.3.6. ASEAN
5.2.6.1.3.7. Rest of Asia Pacific
5.2.6.1.4. Middle East & Africa (MEA)
5.2.6.1.4.1. Saudi Arabia
5.2.6.1.4.2. South Africa
5.2.6.1.4.3. UAE
5.2.6.1.4.4. Rest of MEA
5.2.6.1.5. South America
5.2.6.1.5.1. Argentina
5.2.6.1.5.2. Brazil
5.2.6.1.5.3. Rest of South America

6.1. Market Dynamics and Trends
6.1.1. Growth Drivers
6.1.2. Restraints
6.1.3. Opportunity
6.1.4. Key Trends

6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
6.2.1. Key Insights
6.2.1.1. By Delivery Technology
6.2.1.2. By Route
6.2.1.3. By Indication
6.2.1.4. By Distribution Channel
6.2.1.5. By End User
6.2.1.6. By Country

7.1. Market Dynamics and Trends
7.1.1. Growth Drivers
7.1.2. Restraints
7.1.3. Opportunity
7.1.4. Key Trends

7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
7.2.1. Key Insights
7.2.1.1. By Delivery Technology
7.2.1.2. By Route
7.2.1.3. By Indication
7.2.1.4. By Distribution Channel
7.2.1.5. By End User
7.2.1.6. By Country

8.1. Market Dynamics and Trends
8.1.1. Growth Drivers
8.1.2. Restraints
8.1.3. Opportunity
8.1.4. Key Trends

8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
8.2.1. Key Insights
8.2.1.1. By Delivery Technology
8.2.1.2. By Route
8.2.1.3. By Indication
8.2.1.4. By Distribution Channel
8.2.1.5. By End User
8.2.1.6. By Country

9.1. Market Dynamics and Trends
9.1.1. Growth Drivers
9.1.2. Restraints
9.1.3. Opportunity
9.1.4. Key Trends

9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
9.2.1. Key Insights
9.2.1.1. By Delivery Technology
9.2.1.2. By Route
9.2.1.3. By Indication
9.2.1.4. By Distribution Channel
9.2.1.5. By End User
9.2.1.6. By Country

10.1. Market Dynamics and Trends
10.1.1. Growth Drivers
10.1.2. Restraints
10.1.3. Opportunity
10.1.4. Key Trends

10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
10.2.1. Key Insights
10.2.1.1. By Delivery Technology
10.2.1.2. By Route
10.2.1.3. By Indication
10.2.1.4. By Distribution Channel
10.2.1.5. By End User
10.2.1.6. By Country

11.1. Alnylam Pharmaceuticals
11.2. Novartis
11.3. Novo Nordisk (Dicerna)
11.4. Arrowhead Pharmaceuticals
11.5. Ionis Pharmaceuticals
11.6. Silence Therapeutics
11.7. Regeneron
11.8. Sanofi
11.9. Moderna
11.10. Roche
11.11. Amgen
11.12. Eli Lilly
11.13. Comanche Biopharma
11.14. Quark Pharmaceuticals
11.15. Astellas
11.16. Other Prominent Players

12.1. List of Secondary Sources
12.2. Key Country Markets- Macro Economic Outlook/Indicators